OBOOK Holdings announced the completion of its OwlPay global settlement platform infrastructure for stablecoin-enabled cross-border payments in 2025, alongside expanding U.S. regulatory licenses to 39 states and integrating key payment networks like Circle and Visa Direct. The company reported $7.9 million in revenue for 2025, primarily from existing businesses, while investing heavily in building its payment infrastructure, resulting in a net loss of $31.9 million due to share-based compensation and listing costs. OwlPay Harbor now serves 36 enterprise clients with over $6 billion in aggregate annual payment volume, positioning the company for commercial expansion and enterprise adoption in 2026. OBOOK also secured $10 million in convertible funding to support global growth and continues to pursue additional licenses in key markets worldwide.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...
Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...
Zcash (ZEC) has gained over 16% in the past week, rallying from lows near $368 to around $552 following an 11% jump in one session. This surge is driven by anticipation of the Ironwood shielded pool upgrade expected around July 28, which addresses a ...
Greenwich LifeSciences is developing GLSI-100, an immunotherapy targeting HER2-positive breast cancer, currently in Phase 3 trials. The drug showed a 70-80% reduction in cancer recurrence in Phase 2b, outperforming existing treatments with no serious...
